Articles tagged with Breast Cancer
Researchers at Washington University in St. Louis have developed a predictive model using tumor biomarkers and imaging parameters to forecast chemotherapy response. The model's accuracy reaches 0.94, allowing for early adjustments to treatment plans and reduced use of toxic chemotherapy drugs.
Researchers found a higher De Ritis ratio to be an independent risk factor for cancer progression in high-risk NMIBC patients. Non-BCG treatment was also identified as a risk factor for recurrence.
Researchers employed iTRAQ based quantitative proteomics to characterize protein alterations in fibroepithelial lesions (FELs) of the breast. The study identified three candidate biomarkers: MUCL1, HTRA1, and VEGFD, which were uniquely expressed in FAD, borderline, and malignant PTs, respectively.
Researchers at EPFL found that certain progestins in hormonal contraceptives can stimulate cell proliferation in the breast, while others do not. This suggests that informed choices about contraceptive composition may help prevent breast cancer risk.
Researchers at University College London have pioneered a single-dose radiotherapy approach for breast cancer treatment that is as effective as traditional radiotherapy and avoids potential damage to nearby organs. The treatment, TARGIT-IORT, has been shown to reduce the risk of fatal cardiovascular disease and other cancers in patients.
The ECOG-ACRIN Cancer Research Group presented new research results on patients with breast and HPV-associated throat cancers. A phase III trial found platinum chemotherapy ineffective in preventing recurrence of basal-like triple-negative breast cancer, while a study on severe joint pain in postmenopausal women with hormone receptor-p...
Researchers are investigating CAV1's dual role in tumor metastasis and suppression using machine learning-based analyses of super-resolution microscopy. They leverage computer vision and AI to automatically analyze data, capturing three-dimensional coordinates with nanometer resolution.
Even among insured individuals, up to 10% of cancer survivors delayed follow-up care due to financial constraints. Financial stress and anxiety hinder timely survivorship care, particularly among vulnerable populations such as racial minorities, women, and those with lower incomes.
Researchers found socioeconomic and racial inequities in breast cancer screenings before and during the pandemic. The study analyzed data from a large statewide nonprofit community health care system, revealing significant disparities among sociodemographic groups.
A new study using data from the Black Women's Health Study found no association between moderate or heavy use of hair relaxers and breast cancer risk in black women. However, heavy users of lye-containing products were found to have a 30% increased risk of estrogen receptor-positive breast cancer.
The study found a 49% decrease in breast cancer screening mammograms completed across Washington state, with significantly larger decreases for non-white women. Rural women saw a 59% reduction in mammograms, while urban women experienced a 50% drop.
A Spanish research team has developed a low-cost, easy-to-use biosensor to detect breast cancer in its earliest stages. The biosensor provides results in under an hour and can help address limitations of current diagnostic methods.
A study identified a tumor marker that can predict which breast cancer patients will benefit from early HER2 targeted therapy, helping to avoid disease relapse. The research found that low or absent MLH1 and PMS2 gene expression may indicate an increased risk of death from the disease.
A new study shows that breast cancer treatments, including chemotherapy, do not significantly increase the risk of Covid-19 infection or death. Researchers analyzed data from over 3,000 women treated for breast cancer during the pandemic and found that only 2% contracted the virus.
A new study reveals that breast cancer survivors have a 20-44% higher risk of developing new cancer diagnoses compared to healthy individuals. The research identifies specific breast cancer subtypes and diagnosis ages associated with increased risk of subsequent primary cancers.
A large survey of women in California found significant racial and ethnic differences in personal care product use, with Black women more heavily exposed to endocrine-disrupting chemicals. The study aims to fill the gap in data on products used by women of color and informs guidance for self-protection and policy development.
High levels of RANK protein trigger senescence in early stages of tumors, delaying their onset, but promote stem cell accumulation and tumour growth in advanced stages. This discovery sheds light on the complex mechanisms underlying breast cancer development and progression.
Researchers at the University of Zurich have developed a new technology called SHREAD that enables cancer tumors to produce therapeutic agents on demand, reducing side effects and improving delivery of Covid-related therapies.
A Phase 1 study of Z-endoxifen in patients with solid tumors reported partial responses in three patients and prolonged stable disease in eight. The study suggests that Z-endoxifen can benefit patients who have progressed on tamoxifen treatment, particularly those with desmoid tumors.
Breast cancer researchers followed the progression of cancer in an animal model and found a path that transforms slow-growing ER+/HER2+ cancer into fast-growing ER-/HER2+ cancer. The study suggests different treatments may be needed for each subtype, depending on the path the cells follow.
A new study suggests that cardioprotective drugs during adjuvant breast cancer therapy may not be necessary for most patients, especially those at low risk of heart disease. The research found no significant differences in heart function between patients who received these medications and placebos.
Researchers found that lasofoxifene outperformed fulvestrant in reducing primary tumor growth and preventing metastasis in the lung, liver, bone, and brain. Additionally, lasofoxifene prevents unwanted side effects, including menopausal-like symptoms.
Researchers discovered a mechanism behind Herceptin resistance in HER2-positive breast cancer cells, citing increased IGF2/IRS1 signaling. A new approach may help overcome this resistance, offering hope for refractory breast cancer patients.
A new study finds that non-Hispanic African American women with triple-negative breast cancer have a 28% increased risk of death compared to their white counterparts. The disparity is attributed to lower rates of surgery and chemotherapy, as well as differences in tumor biology and socioeconomic factors.
A study published in the European Journal of Preventive Cardiology found that nearly one in four heart failure patients experience depression or anxiety, compared to 23% of breast cancer patients, 22% of prostate cancer patients, and 15% of digestive organ cancer patients. Heart failure patients are also at a higher risk of developing ...
Researchers created an RNA atlas detailing the diverse cells in healthy and cancerous breast tissue, revealing changes that occur during cancer development. The study provides a high-resolution view of breast tissue cell types and will be an important resource for breast cancer research.
Scientists at Sanford Burnham Prebys Medical Discovery Institute identified lipid kinases as essential for balancing cellular metabolism and promoting overall health. The findings support targeting these proteins as a promising approach to treating diseases like cancer.
Moffitt researchers found that inhibiting TIM-3 enhances immune cell activity and prevents tumor growth in mice. The study suggests targeting TIM-3 to activate the STING pathway in dendritic cells as a potential therapy for certain types of cancer.
Researchers have developed a novel nano-carrier to deliver the Chinese medicine compound gambogic acid, enhancing its anti-cancer effect and reducing off-target toxicity. The treatment shows promise in treating triple-negative breast cancer with improved efficacy and reduced damage to organs.
The BreastPathQ Grand Challenge produced encouraging results, indicating a path toward integrating artificial intelligence to streamline clinical assessment of breast cancer. Thirty-nine teams from 12 countries developed automated methods for analyzing microscopy images of breast tissue and assessing pathology.
A new study suggests that CDK4 and CDK6 inhibitors can improve immune-cell therapies for treating recurrent ER-positive metastatic breast cancer. The study found that these inhibitors cause breast tumors to secrete chemokines that attract T cells, improving patients' response to cancer immunotherapies.
A Danish study of over 173,000 women found that girls with a higher BMI during childhood had lower breast cancer risks both before and after menopause. The research suggests an inverse association between childhood BMI and breast cancer risk, but further studies are needed to understand the underlying mechanisms.
A study of over 400,000 UK adults found that higher BMI, body fat, and larger waist and hips pose similar risks for developing 10 common cancers. The researchers estimated that excess weight could be responsible for around 40% of endometrial and uterine cancer cases.
A study reveals nearly 30% of breast cancer patients convert to HER2-low status, offering potential treatment opportunities for hard-to-treat tumours. The findings also suggest that HER2-low expression is more frequent in hormone receptor-positive tumours.
Researchers have developed a six-color imaging platform inspired by mantis shrimp eyes to accurately label tumors in mice and visualize lymph nodes near breast cancer tumors. The system detected cancerous tissue in 92% of cases and successfully integrated into the operating room without disrupting surgeons' workflow.
A study at Karolinska Institutet found that low PDGFRb protein levels are associated with better radiotherapy results in women with early-stage DCIS. Combining PDGFRb blocking drugs may improve treatment efficacy.
Risk-reducing mastectomy saves lives of women with hereditary or other risk factors, but also considers quality-of-life issues. Women with BRCA1 and BRCA2 gene mutations have a very high lifetime risk of developing breast cancer.
Researchers are testing cognitive behavioral therapy called Memory and Attention Adaptation Training (MAAT) to improve memory problems and emotional resilience among breast cancer survivors. The study aims to evaluate the effects of MAAT and supportive therapy on cognitive dysfunction after chemotherapy.
Researchers cultivated tumor microenvironments using metastatic triple-negative breast cancer cells and studied the genetic information of entire systems. They found that cellular communication in the microenvironment drives physiological changes in tumor behavior, including growth and movement.
A study at ESMO Breast Cancer 2021 Virtual Congress reveals breast cancer survivors experience varying levels of symptoms after treatment, with some requiring active symptom management. Patients with comorbidities, such as heart disease and diabetes, are more likely to experience a high symptom burden.
A new study reveals that higher body mass index (BMI) is associated with worse survival in early breast cancer patients but improved survival in advanced disease. The 'obesity paradox' highlights the need to understand the biological basis of obesity impacts on breast cancer diagnosis and treatment.
Fertility concerns significantly affect young women with hormone receptor-positive breast cancer treatment decisions, new research shows. Women who express fertility concerns are more likely to choose not to start or discontinue endocrine therapy.
The COVID-19 pandemic led to a significant decline in cancer screenings for breast, colorectal, and prostate cancers. According to the study, screening rates dropped by an estimated 22% during the pandemic.
Breast cancer patients experience frequent job changes after diagnosis, with around ten percent reporting involuntary changes. The study suggests that a supportive work environment and understanding from managers can facilitate a satisfactory return to work.
The 2021 ESMO Breast Cancer Congress presented nearly 200 studies on various aspects of breast cancer, including adjuvant, neoadjuvant, and immunotherapy. The congress also highlighted the importance of personalized follow-up care for breast cancer patients.
Researchers found that sanguinarine, a natural compound, reduces cell viability and growth in triple-negative breast cancer cells. The treatment activated different genes in cells from African American ancestry, suggesting potential therapeutic benefits for this population.
Recent studies at VCU Massey Cancer Center discovered a link between prolactin and breast cancer development. The hormone was found to act as a major contributor to breast cancer growth and could inform the creation of targeted drugs to treat multiple forms of the disease.
A study by the University of Southern Denmark found that Football Fitness improves balance, strengthens muscles, and increases bone density in women treated for breast cancer. The 12-month training program reduced the risk of falls and broken bones, making everyday activities easier.
Researchers at Dartmouth's Norris Cotton Cancer Center have found that cycling between estrogen treatment and anti-estrogen therapies can dramatically increase the duration of tumor regression in mice. This unconventional approach suggests treating short-term with estrogen before resistance occurs, leading to better long-term control.
A small proportion of women with anti-estrogen treatment after breast cancer surgery have worse outcomes due to mutations in the estrogen receptor gene. Research found that 1% of breast cancer cases already at initial diagnosis have these resistant mutations, leading to poorer response to hormonal treatment and higher risk of recurrence.
Researchers discovered that distinct Notch family members are modified differently by phosphorylation, leading to opposite effects on transcriptional activity and oncogenic behavior. The study suggests that targeting PIM or Notch proteins may provide new treatment options for hormone-dependent breast cancer with poor prognosis.
A new study from Ohio State University reveals that women with high-risk profiles struggle to access genetic counseling and testing due to financial constraints. The research emphasizes the need for greater transparency in healthcare pricing and policies to eliminate barriers to early cancer detection.
A global phase 3 clinical study confirms the effectiveness of targeted antibody drug conjugates against refractory metastatic triple-negative breast cancer. The ADC drug sacituzumab govitecan delivered a high dose of a cancer-killing drug to tumor cells, improving progression-free and overall survival.
A comprehensive systematic review of epidemiological research found a link between certain endocrine-disrupting chemicals and increased breast cancer risk. For example, DDT, PCBs, and PFOA were associated with higher breast cancer incidence in some studies, while phytoestrogens like genistein showed potential protective effects.
A new study from the University of Bergen reveals that targeted therapy using PARP inhibitors can be effective in treating early-stage triple negative breast cancers. The study found a significant response rate among patients not harboring germline mutations, highlighting a potential for improved personalized treatment.
A study published in JAMA Network Open found that treating older patients with early-stage breast cancer did not improve survival rates and may cause harm. Researchers analyzed data from over 3,000 women aged 70 and found that omitting treatments like sentinel lymph node biopsy and radiotherapy did not affect recurrence or survival rates.
Researchers have identified specific super-enhancers that stimulate the activity of critical cancer genes in triple-negative breast cancer (TNBC). The study reveals that deleting certain super-enhancers can reduce tumour cell growth and improves survival chances. Dr Rebecca Chin and Dr Wang Xin's findings may lead to the development of...
A new study found that granddaughters whose grandmothers were exposed to DDT have higher rates of obesity and earlier first menstrual periods. This may increase the granddaughters' risk for breast cancer, high blood pressure, diabetes, and other cardiometabolic diseases.
Researchers at HSE University have identified key molecules responsible for breast cancer metastasis by developing an algorithm that recreates the networks of intercellular interactions in cancer cells. The program detects prognostic genes, with transcription factor E2F1 playing a major role in predicting patient outcomes.
Researchers found that breast cancer cells trigger uncontrolled inflammation and remodel tissue, making the cancer more aggressive. The study suggests targeting inflammatory pathways could improve treatment outcomes for pregnant women with breast cancer.